Depreotide is an ingredient in the diagnostic aid (radioactive imaging agent). Technetium Tc 99m labeled depreotide is a scintigraphic imaging agent that identifies somatostatin receptor-bearing pulmonary masses in patients presenting with pulmonary lesions on computed tomography and/or chest x-ray who have known malignancy or who are highly suspect for malignancy. Adverse events were evaluated in clinical studies of 647 adults. Deaths did not occur during the clinical study period. After Technetium Tc 99m Depreotide Injection, serious adverse events were not reported. Headache was the most commonly reported adverse event. EMA withdrew depreotide containing agent NeoSpect.

Lutrelin is an agonist of gonadotropin-releasing hormone receptor exerting antineoplastic properties.

Lotilibcin (WAP-8294A2) is an antibiotic originally isolated from Lysobacter sp. It is active against methicillin-resistant gram-positive bacteria. Lotilibcin antimicrobial activity is due to lysis of the bacterial membrane, and its membrane-disrupting effect depends on the presence of menaquinone, an essential factor for the bacterial respiratory chain. It was developing for the treatment of susceptible bacterial infections

Codactide is a synthetic octadecapeptide, an analog of adrenocorticotropin. When administered intravenously, codactide produced a prolonged adrenal stimulatory action, as measured by high 11-hydroxycorticosteroid level.

Geclosporin (Cyclosporine) is an immunosuppressive agent, that is used to prevent rejection of a transplanted organ by the body. Geclosporin is isolated from a fungus, Beauveria nivea, and was first discovered in 1970. By suppressing the immune system, this drug prevents white blood cells from rejecting the transplanted organ. Geclosporin primarily does this by suppressing T cells and T cell cytokine production, but also acts in other ways, for example by inhibiting growth and activation of B cells and antigen presenting cells, and by reducing antibody production. Geclosporin is usually combined with other compounds, and has been studied as potential treatment for a large range of disorders. It is used for the treatment of several other conditions, such as severe recalcitrant plaque psoriasis, severe active rheumatoid artritis, and to prevent rejection of donor cells as a result of bone marrow transplantation. Relapse after discontinuation of this compound is to be expected, and therefore, patients should receive maintenance therapy at the lowest effective dosage. The most common adverse events are hypertrichosis, gingival hyperplasia, and neurological and gastrointestinal effects. Renal dysfunction is also possible, but irreversible damage is rare.

Omiganan (previously known as MBI-226), is a synthetic, linear, 12 amino acid, cationic peptide analog of indolicidin, being developed as a topical gel for prevention of catheter-associated infections. In September 2000, a phase III trial of omiganan for the potential prevention of catheter-related bloodstream infections was initiated. In July 2018 was completed phase III clinical trial where was evaluated the long-term safety of once-daily application of omiganan topical gel in subjects with severe papulopustular rosacea. In addition, omiganan successfully completed phase II clinical trials where was determined its safety/tolerability in patients with mild to moderate atopic dermatitis and in human subjects with facial acne vulgaris. Besides, omiganan is ongoing phase II to explore the efficacy and pharmacodynamic effects of its topical gel in facial seborrheic dermatitis.

Selepressin (FE 202158) was designed as a selective and short-acting vasopressin type 1a receptor (V(1a)R) agonist. This drug was developed for the treatment of vasodilatory hypotension in shock. Selepressin successfully completed phase IIa clinical trial, where was found that in septic shock patients, selepressin 2.5 ng/kg/minute was able to rapidly replace norepinephrine, improve fluid balance and shorten the time of mechanical ventilation.

Tribendilol is a beta-adrenoceptor antagonist. Tribendilol has significant antihypertensive action but is associated with a high incidence of orthostatic side effects.